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Patients with chronic kidney disease (CKD) do not always receive care consistent with guidelines, in part due to
complexities in CKD management, lack of randomized trial data to inform care, and a failure to disseminate best
practice. At a 2007 conference of key Canadian stakeholders in kidney disease, attendees noted that the impact of
Canadian Society of Nephrology (CSN) guidelines was attenuated given limited formal linkages between the CSN
Clinical Practice Guidelines Group, kidney researchers, decision makers and knowledge users, and that further
knowledge was required to guide care in patients with kidney disease. The idea for the Canadian Kidney Knowledge
Translation and Generation Network (CANN-NET) developed from this meeting. CANN-NET is a pan-Canadian network
established in partnership with CSN, the Kidney Foundation of Canada and other professional societies to improve the
care and outcomes of patients with and at risk for kidney disease. The initial priority areas for knowledge translation
include improving optimal timing of dialysis initiation, and increasing the appropriate use of home dialysis. Given the
urgent need for new knowledge, CANN-NET has also brought together a national group of experienced Canadian
researchers to address knowledge gaps by encouraging and supporting multicentre randomized trials in priority areas,
including management of cardiovascular disease in patients with kidney failure.
Keywords: Kidney disease, Knowledge translation, Clinical trialsRésumé
Les patients atteints d’insuffisance rénale chronique (IRC) ne reçoivent pas toujours les soins recommandés dans les
lignes directrices en raison de la complexité du traitement de l’IRC, de l’absence de données probantes sur
différents aspects de l’IRC et d’un manque de diffusion des bonnes pratiques. Lors d’une conférence tenue en 2007
et réunissant différents acteurs clés impliqués en néphrologie, les participants ont attribué le peu d’impact des
lignes directrices de la Société canadienne de néphrologie (SCN) à un manque de communication et d’arrimage
entre le comité chargé des lignes directrices cliniques de la SCN et les chercheurs, les décideurs et les utilisateurs
(Continued on next page)* Correspondence: Braden.Manns@albertahealthservices.ca
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada
2Department of Community Health Sciences, University of Calgary, Calgary,
Alberta, Canada
Full list of author information is available at the end of the article
© 2014 Manns et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Manns et al. Canadian Journal of Kidney Health and Disease 2014, 1:2 Page 2 of 10
http://www.cjkhd.org/content/1/1/2(Continued from previous page)
de connaissance. De plus, les participants ont aussi mentionné la nécessité d’acquérir plus de connaissances afin
d’optimiser les soins de patients atteints d’IRC. L’idée du Canadian Kidney Knowledge Translation and Generation
Network (CANN-NET) s’est développée suite à cette conférence. CANN-NET est un réseau pancanadien réunissant la
SCN, la Fondation canadienne du rein et différentes sociétés savantes professionnelles et dont la visée est
d’améliorer les soins et la survie des patients atteints ou à risque de maladie rénale. La détermination du moment
optimal d’initiation de la dialyse ainsi que l’utilisation accrue des modalités de dialyse à domicile font partie des
priorités initiales de transfert de connaissance identifiées par CANN-NET. De plus, compte tenu d’un besoin continu
de nouvelles connaissances, CANN-NET a aussi créé un groupe national de chercheurs canadiens afin d’accroître les
connaissances et l’acquisition de données en encourageant et en supportant des études cliniques randomisées et
multicentriques sur des sujets jugés prioritaires tels que le traitement de la maladie cardiovasculaire chez les
patients atteints de maladie rénale.Background to the need for the Canadian Kidney
Knowledge Translation and Generation Network
Chronic kidney disease (CKD) is common [1,2] and
often coexists with, or is a complication of, diabetes,
hypertension, and vascular disease [3]. Management of
patients with CKD is complicated by the lack of ran-
domized trial data to inform clinical care [4]. Even where
good quality data from trials exist, results are often not
translated into practice. This results in care of CKD pa-
tients that is not consistent with guidelines [5-7].
In 2008, the Canadian Society of Nephrology (CSN)
published clinical practice guidelines for the care of pa-
tients with kidney disease [1]. The guidelines addressed
the many diverse aspects of care for these patients, in-
cluding management of hypertension and diabetes,
anemia, and abnormalities of mineral metabolism. The
guidelines identified many areas where further know-
ledge was required to guide care, and their impact may
have been limited by the lack of formal linkages between
the CSN Clinical Practice Guideline Group, kidney re-
searchers, decision makers and knowledge users such as
primary care physicians, regional renal programs, the
Kidney Foundation of Canada, and patients themselves.
Recognizing the lack of capacity in knowledge translation
and randomized trials [4] in kidney disease, two Canadian
conferences: Horizons 2000 and Horizons 2015 were held
to develop a Canadian strategic research agenda. The Hori-
zons conferences brought together key stakeholders from
the kidney research community and organizations inclu-
ding the Kidney Foundation of Canada (KFOC), the CSN,
the Canadian Society of Transplantation (CST), and the
Canadian Institutes for Health Research (CIHR).
At the Horizons 2000 conference, participants agreed to
develop a transdisciplinary research training program to en-
hance capacity for kidney research in Canada. The Kidney
Research Scientist Core Education and National Training
Program (KRESCENT) program (www.krescent.ca ) deve-
loped from this meeting as a unique research training pro-
gram for kidney scientists and allied health professionals [8].
The Horizons 2015 conference (held in 2007), whose focuswas on enhancing excellence and capacity in kidney research,
prioritized two other initiatives, including creating a network
of kidney researchers across Canada, and creating stronger
links between kidney researchers and knowledge users.
The CAnadian KidNey KNowledge TraNslation and GEn-
eration NeTwork (CANN-NET) was initiated in 2010 with
funding from CIHR to address the Horizons 2015 priorities.
CANN-NET developed linkages between Canadian kidney
disease guideline producers, knowledge translation specia-
lists and knowledge users to improve knowledge disse-
mination and the care of patients with kidney disease
(Figure 1). CANN-NET has also brought together a national
group of experienced Canadian researchers to address
knowledge gaps by coordinating and executing multicentre
clinical trials to address the need for new knowledge. To
ensure that CANN-NET is relevant and responsive to
knowledge user needs, CANN-NET partnered with key
knowledge users from the kidney community, primary care,
other partners with a vested interest in kidney health,
experts in knowledge translation and global clinical trials.
CANN-NET objectives
The overall goal of CANN-NET is to improve the care
and outcomes of patients with kidney disease. This will be
achieved by 1) linking an active clinical practice guidelines
committee with relevant knowledge users, ensuring best
practice for patients with CKD through knowledge dis-
semination of important guidelines to knowledge users,
and 2) identifying knowledge gaps in kidney disease that
can be addressed through large studies facilitated by a
collaborative network of nephrology researchers.
How CANN-NET developed to fulfill these
objectives
To meet its diverse objectives, as illustrated in Figure 2,
CANN-NET is organized into several working committees,
including the knowledge user committee, the knowledge
translation committee, the Pediatrics committee, and the
Clinical Trials Scientific Committee. CANN-NET also has
a close working relationship with the CSN guidelines
Figure 1 CANN-NET Partners and Knowledge Users.
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through video or tele-conference, and biannual face-to-face
meetings. Terms of reference are available for each com-
mittee on www.CANN-NET.ca; the committee purpose, as
well as duties and responsibilities are presented in Table 1.
Clinical Practice Guidelines Committee
CANN-NET works closely with the CSN’s existing clinical
practice guidelines committee [9] which collaborates with
Kidney Disease: Improving Global Outcomes (KDIGO), an
international group that develops nephrology clinical prac-
tice guidelines [10]. To increase efficiency, the CSN clinical
practice guidelines committee does not replicate guidelines
produced by KDIGO; instead it develops commentaries on
KDIGO guidelines to increase the relevance of these guide-
lines to Canadian practice and to facilitate guideline imple-
mentation and knowledge translation (KT) activities.
In CANN-NET priorities areas where existing guide-
lines are not available, CANN-NET has collaborated
with the CSN guidelines committee to establish “ad hoc”
guideline working groups.Knowledge User Committee
In Canada, the care of patients with kidney failure is gener-
ally organized and funded through geographically based
kidney care programs with dyad medical and administra-
tive lead structures. These decision makers are unique
since they typically hold multiple roles within kidney care
programs, serving as administrators, clinicians, researchers
and policy makers. CANN-NET has established a commit-
tee of these knowledge users, with the primary goal being
to inform CANN-NET priorities for new clinical trials and
to prioritize and facilitate knowledge translation activity.
While optimizing care and outcomes in CKD requires
knowledge dissemination and new research across many
areas of care, it is clear that not all areas can be addressed
simultaneously. A mechanism for prioritizing action that
incorporates the perspectives of patients with kidney dis-
ease and kidney-relevant decision makers was developed,
considering a number of dimensions including a) whether
there is a high level of evidence that adherence to a
guideline will improve clinical or economic outcomes, b)
whether clinical practice related to a particular guideline
Figure 2 CANN-NET Organizational Chart.
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clinical practice to improve concordance with guidelines.
The knowledge user committee helps to frame the im-
plications of CANN-NET activities in terms of health care
system functioning and impact, assessed over different
time horizons.
Knowledge Translation (KT) Committee
CANN-NET’s approach to KT is grounded in integrated
knowledge translation [11] and involves a range of key
knowledge users and their organizations (Figures 1 and 2).
The KTcommittee works with the knowledge user commit-
tee to identify key guideline messages, determines the KT
activities (expanded below), and communicates key mes-
sages in a format that meets the needs of knowledge users.
For each CANN-NET KT project, key activities are
guided by the Knowledge to Action Cycle [12] (Figure 3)
including the following steps:
 Examining barriers and facilitators using a multilevel
approach that recognizes patient-, provider- and
system-level factors Development of key themes and messages
 Selecting, tailoring and implementing interventions to
address these barriers and facilitators, which may include:
 Writing a series of clinical and scientific
summaries for various audiences
 Facilitating the annual CSN/Canadian Association
of Nephrology Administrators symposium at the
annual CSN meeting – an opportunity for dialog
and education with renal program administrators
from across Canada
 Creating key educational materials in priority
areas, including infographics and animated white
boards, aimed at patients and providers
 Working with local knowledge users including
regional/provincial renal programs to develop
tool kits to assist them in developing the local
best strategy for getting the messages out
 Working in conjunction with the Canadian Organ
Replacement Registry (CORR) to customize annual
facility reports to include recommendations to
increase achievement of quality care indicators in
CANN-NET priority areas
Table 1 Terms of reference for CANN-NET committees
CANN-NET
Committee




To work with the Executive Committee and all of the
CANN-NET working committees to guide CANN-NET
priorities for new clinical trials and knowledge translation
activity, and to facilitate knowledge translation activities
• To work in partnership with the Guidelines Committee
to establish priorities for the new CSN guidelines
• To work in partnership with the Knowledge Translation
Committee to establish priorities for new Knowledge
Translation Activities,
• To facilitate creation of a network of key medical and
administrative leads of renal programs and multidisciplinary
CKD programs across Canada
• To work in partnership with the Clinical Trials Group to
provide feedback on priority areas for new knowledge
• To ensure adequate communication between knowledge





To define, develop, monitor and evaluate
knowledge translation activities
• To facilitate the dissemination and uptake of best practices for
the care of patients with or at risk of kidney disease across Canada.
• To develop a knowledge translation plan, using the
knowledge to action cycle, to address priority areas
established by the knowledge user committee
• To conduct research to determine the optimal methods of
knowledge dissemination to enhance the care of patients
with kidney disease
• To develop a framework for the evaluation of knowledge
translation activities, including information to collect at
baseline and after completion of KT activity





To define, develop, monitor and evaluate knowledge
creation and translation activities relevant for Canada.
• To facilitate the dissemination and uptake of best practices for the
care of children with or at risk of kidney disease across Canada.
• To develop knowledge translation tools relevant for Pediatric
Nephrology
• To develop a framework for the utilization of databases and
registries in Pediatric relevant kidney research
• To assist and guide in the design of clinical trials including
those trials which address knowledge gaps and knowledge
user priorities, ensuring a focus on patient centred outcomes





To determine which submitted kidney clinical trials should
receive CANN-NET support or endorsement based on their
merits, including their feasibility and importance to Nephrology
• To review and evaluate clinical trial proposals
• To recommend which trials should receive CANN-NET support
or endorsement
• To develop and implement clinical trial review criteria and
mechanism
• To assist and guide in the design of nephrology clinical trials
including those trials which address the Knowledge User Group
priorities, ensuring a focus on patient centered outcomes
• To liaise with the CANN-NET Knowledge Users Group and CSN
Clinical Practice Guidelines Committee to develop clinical trial priorities
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and outcomes to determine if the KT activities are
improving care and outcomes.
Clinical Trials Committee
Since 2011, the Clinical Trials Committee has accepted
requests for protocol review from nephrology researchersacross Canada. It reviews the science, logistics, and feasi-
bility of proposed trials using a transparent mechanism
to identify the most promising studies, and critiques pro-
tocols to ensure that they are of the highest scientific
standards. This critique is fed back to the investigators as
constructive advice, in an iterative process if necessary,
which the goal of improving the chances of the trials
Figure 3 Knowledge to Action Cycle.
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fully. To facilitate multi-center trials, the Clinical Trials
Committee is building a registry of research interests, ex-
pertise and resources across Canada. The committee is
also interested in promoting the conduct of high quality
trials that address priority areas but are initiated outside
of Canada. Such central organization and support is cri-
tical to perform high quality clinical trials particularly in
conditions affecting a limited number of people (e.g.
kidney disease in children, vasculitis).
In 2010, the heads of renal programs were surveyed
across Canada to determine the most important prior-
ities for new clinical trials and two topics were identified
by the Knowledge User committee as initial priorities.Although it was not intended that the Clinical Trials
committee would plan trials from inception, members of
the committee felt these initial priorities merited add-
itional attention and resources. The top identified prior-
ities were to determine the health impact of targeting
different phosphate levels in patients on dialysis, and to
determine the impact of aldosterone antagonism in re-
ducing morbidity and mortality in dialysis patients. In
collaboration with the Canadian Network and Centre for
Trials Internationally (CANNeCTIN) and the Population
Health Research Institute (PHRI) (two Canadian consor-
tiums conducting trials investigating lowering cardiovas-
cular risk), two pilot randomized trials addressing the
feasibility of large trials to address these important
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tient followup in November 2013).
Pediatrics Committee
Current treatments for children with kidney disease are
often supported by weak evidence or inferences made
from clinical trials performed in adults. Therefore, in
many management decisions, pediatric Nephrologists
often have to use anecdotal or centre experience to
guide therapy. To effectively conduct clinical research in
children with kidney disease, multicentre trials and the
expertise of researchers familiar with methodological
challenges in performing clinical research in children are
required. The Pediatrics Committee, which consists of
members of the Canadian Association of Pediatric Ne-
phrologists (CAPN), therefore has two main goals. The
first goal is to identify areas specific to pediatric kidney
disease which are in urgent need of evidence generation
and knowledge translation to coordinate national and
international efforts to achieve these goals. The second
is to ensure that guidelines production and knowledge
translation initiatives which are geared towards the care
of adults with kidney disease, also consider the needs
and are inclusive of children with kidney disease (for
example: the timing of dialysis initiation, described
below, was deemed relevant to child nephrology care
and thus includes a pediatric-specific component). This
is achieved by inclusion of Pediatrics Committee mem-
bers in guideline commentary groups described above,
membership of Pediatrics committee members in the
Knowledge Translation and Clinical Trials committees
and frequent communication between the Pediatrics
committee and other relevant CANN-NET committee
groups. This committee will also work with relevant
knowledge partners to build a core group who can de-
velop skills in clinical practice guideline productions,
and knowledge translation relevant for children with
kidney disease. Initial priority areas were identified by
surveying CAPN membership, and include manage-
ment of childhood nephrotic syndrome.
CANN-NET partners and knowledge users:
leveraging existing partnerships and building
new ones
Partnerships are at the heart of all KT activity. Effective
KT is dependent on effective bidirectional exchanges be-
tween researchers and knowledge users. To deliver on
its KT mandate, CANN-NET will build on the strengths
of others active in this field, create synergies, learn from
existing experience and best practice, and avoid duplica-
tion of effort. Knowledge users play a key role in this ini-
tiative (Figure 1), and the Kidney Foundation of Canada
is a funding partner and key knowledge user given its
broad interest in optimizing care of patients with CKD.Other knowledge users include the leads of the provin-
cial renal programs across Canada.
Given that CANN-NET cannot exist in isolation from
other professional groups with complementary interests
and scope, CANN-NET will also work closely with the
following partners (Figure 1):
 Canadian Society of Nephrology (CSN), Canadian
Society of Transplantation (CST), the Canadian
Association of Pediatric Nephrologists (CAPN), and
the Renal Pharmacists Network (RPN) – these are the
professional societies of nephrologists and pharmacists
in Canada caring for all patients with kidney disease,
including adults, those with kidney transplants and
children with kidney disease. Involvement of each
will be critical since CANN-NET’s scope includes the
continuum of patients with kidney disease and since
guidelines (e.g. initiation of dialysis) and research will
often be directly relevant to all societies.
 Canadian Hypertension Education Program (CHEP)
– This collaboration will be critical where updates of
guidelines include issues related to hypertension.
 Clinical trial networks including the Australasian
Kidney Trials Network (AKTN) –a successful
clinical trials network that has completed several
high profile randomized trials in Nephrology [13] –
and the Canadian Network and Centre for Trials
Internationally (CANNeCTIN) – a national network
funded by the CIHR/CFI Clinical Research Initiative
program to improve the prevention and treatment
of cardiac and vascular diseases and diabetes. The
Population Health Research Institute (PHRI), which
serves as the core Data Coordinating Centre for
CANNeCTIN is also providing support to facilitate
CANN-NET clinical trials of mutual relevance.What are the initial CANN-NET priorities, and why
Initial CANN-NET priorities for new clinical trials were
developed based on knowledge user priorities – which
as noted above related to improving management of car-
diovascular disease in patients with kidney failure. Sub-
sequently, CANN-NET has collaborated on a project
that assessed the research priorities of patients on or
nearing dialysis, their caregivers, and clinicians. The ini-
tial focus on patients on or nearing dialysis relates to the
fact that quality of life of most dialysis patients is ad-
versely affected, and considerable responsibilities are
placed upon them and their caregivers. The method used
was based on the approach successfully used in the UK by
the James Lind Alliance (JLA) involving patients, their care-
givers and clinicians in research priority setting. Initial results
of this exercise are available at http://www.cann-net.
ca/patient-information/research-priorities-survey#results
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Consistent with the Knowledge to Action Cycle [12],
guideline and KT priorities were driven by an initial as-
sessment of gaps in the care of patients with kidney dis-
ease. Knowledge gaps were identified using Canadian
health care administrative data, including data from the
Canadian Organ Replacement Registry (CORR). This
was supplemented through a survey of knowledge users
in 2010 to determine priorities for new clinical practice
guidelines and KT activities. After development of an ex-
haustive list of topics for new guidelines and KT acti-
vities, topics were prioritized using the key dimensions
noted above. Selection of the top priorities was finalized
at a face-to-face meeting of knowledge users. Two prio-
rities for KT were identified by knowledge users from
adult renal programs including optimal timing of dialysis
initiation, and increasing appropriate use of home dialy-
sis, while one priority was identified by pediatric knowledge
users, management of childhood nephrotic syndrome. With
the recent release of the KDIGO guidelines for the care of
patients with chronic kidney disease [14], it is expected
that CANN-NET will develop additional priorities in
nondialysis CKD.
Timing of dialysis initiation
Over the past 10 years CKD patients in Canada are start-
ing dialysis at higher levels of eGFR [15]. While consist-
ent with existing guidelines [16], this practice is not
consistent with recent information from a high quality
clinical trial [13]. Given the potential for delaying ad-
ministration of this very burdensome treatment and cost
savings that might be realized if the new data were used
to influence clinical care, knowledge users prioritized
timing of dialysis initiation for guideline creation and
knowledge translation activity. With respect to this ini-
tiative, each of the CANN-NET committee had prede-
fined roles. The ad-hoc guidelines working group,
established in collaboration with the CSN guidelines
Committee, has completed clinical practice guidelines
regarding the timing of dialysis initiation [17] The
Knowledge User Committee has facilitated creation of
an enduser network including medical and administra-
tive leads of multidisciplinary CKD programs across
Canada. These contacts will be critical for disseminating
guidelines to the health care providers who can use
them to optimize care, and have provided information
about local practice that can guide KT activities.
The Knowledge Translation Committee used CORR
data to establish current patterns of care with respect to
timing of dialysis initiation across Canada, and surveyed
providers to examine barriers and facilitators using a
multilevel approach recognizing patient-, provider- and
system-level issues [18]. After prioritization by theknowledge users, the key messages within clinical prac-
tice guidelines have been developed as the focus of KT
efforts, directed towards the enduser network of CKD
clinics. These messages will be incorporated into pro-
vider and patient directed infographics, animated white-
boards designed for patient education as well as
academic detailing through continuing medical educa-
tion – simultaneously targeting identified patient, and
provider-level barriers. CANN-NET plans to evaluate the
impact of these interventions on CKD clinics within a
controlled trial using CORR data to measure outcomes.
Increasing the appropriate use of home dialysis
The optimal dialysis modality blend has been reported to
be 60-65% hemodialysis and 35-40% peritoneal dialysis.
Home-based therapies (peritoneal and home hemodialysis)
are under-utilized in many Canadian jurisdictions with the
proportion of home-based therapies at 21.6% nationally
and varying between 10 and 40% across centres [19]. In
part, this is because decisions about dialysis modality selec-
tion involve a complicated interplay between health care
provider knowledge and practice, patient and family values,
patient autonomy, clinical benefits/limitations, resource
allocation +/− incentives and geographical variation [20].
Several patient surveys have shown that patient prefer-
ence should be the most important factor in dialysis mo-
dality selection, followed by comparative data on quality
of life, morbidity, rehabilitation potential and survival
[21-26] Other factors to consider are comorbid condi-
tions, social circumstances and cost to patient/health
system. Comparative studies suggest that quality of life,
morbidity, rehabilitation potential and survival appear
equivalent or possibly favour the use of home-based
therapies, particularly in the initial years [27-32]. Despite
this, home dialysis use remains low and variable across
Canadian renal programs.
Based on this and the fact that home dialysis therapies
are less resource intensive than in-center hemodialysis,
increasing the appropriate use of home-based therapies
has been identified as a priority by CANN-NET know-
ledge users. Since this issue is closely linked with timing
of dialysis, knowledge users felt that a coordinated ap-
proach to both issues would be important. The frame-
work for developing this approach will follow that
identified above for timing of dialysis initiation.
Childhood Nephrotic Syndrome
In 2012, the Kidney Disease Improving Global Outcomes
(KDIGO) work group published Clinical Practice Guide-
lines for management of patients with Glomerulonephritis,
which included guidelines for childhood nephrotic syn-
drome. To bridge the gap between available evidence and
practice and identify how best to incorporate the KDIGO
Guidelines into routine care, the Pediatrics Committee
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tice patterns in the management of childhood nephrotic
syndrome. Survey results were compared with recommen-
dations found in the Guidelines. They found potential evi-
dence practice gaps in steroid dosing and duration, use of
steroid-sparing agents and indications for kidney biopsy-the
same areas there they noted high variability in practice. Since
there is no knowledge translation strategy to implement the
KDIGO Guidelines into pediatric nephrology in Canada, the
Pediatrics Committee is developing an active knowledge
translation plan for childhood nephrotic syndrome that in-
cludes development of a standardized national clinical
pathway to promote uptake of evidence into practice.
Moving forward: what is needed to optimize care
and outcomes
Improving care and outcomes for patients with kidney
disease cannot be done in isolation of clinicians, re-
searchers, decision makers and patients. CANN-NET
has received input from all groups, and will work with
these groups to optimize care and outcomes for patients
with kidney disease. Despite developing relationships
with renal programs across Canada, further work to de-
velop links with decision makers in provincial ministries
of health will be required since some knowledge transla-
tion activities may require collaboration with govern-
ment. For instance, managing patients with severe CKD
not yet on dialysis is resource-intensive, but is remuner-
ated at a lower rate than caring for dialysis patients.
Aligning remuneration with important activities may as-
sist appropriate care. Addressing other health-system
barriers that might be identified may also require the
collaboration of health ministries. Given that the initial
CANN-NET initiatives, if successful, will improve patient-
relevant outcomes and reduce health care costs, mutual
collaboration with ministries would seem attractive.
Summary
Through an iterative process, focused on improving the
care of patients with kidney disease, CANN-NET has
developed a robust collaborative framework which inte-
grates clinical research, health outcomes evaluation,
guideline generation and dissemination, and formal
knowledge translation activities across Canada. With
international and multidisciplinary collaborations, the
potential impact of the initiative is far reaching. The ini-
tial activities and focus of CANN-NET on timing of dia-
lysis initiation and dialysis modality selection, topics of
key importance to patients and health care systems alike,
is based on a systematic evaluation of needing to impact
these two processes to improve outcomes. The potential
for further generalization of lessons learned to other
complex chronic conditions, is another potential value
of CANN-NET to the health care community.Abbreviations
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